Impact of Long-acting Bronchodilator- -Corticoid Inhaled Therapy on Ventilation, Lung Function and Breathlessness

Recruiting now · Phase 1/Phase 2

Conditions studied: Copd

In brief

Multicentre, prospective, non-randomised, single-arm, open label, mechanistic study to investigate the mechanism of action of BGF 160 on ventilation pattern complexity and variability

Key facts

Study ID

NCT06110403

Run by

University Hospital, Lille

People needed

35

Starts

2023-09-29

Expected to finish

2026-09-01

Last updated by the study team

2025-12-18

Who can join

Age: 40 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Provision of signed informed consent prior to any study specific procedure
• Female or male subjects aged 40-75 years inclusive at the time of enrolment (Visit 1)
• Documented history of COPD with a post-bronchodilator FEV1/FVC <0.70 and a post-bronchodilator 30 % < FEV1 <70% of predicted normal value (according to ERS 1993 reference values for spirometry ) at screening
• Smoking history > 10 pack-years
• Baseline significant dyspnea with a mMRC ≥ 2

You may not qualify if…

• History or current diagnosis of asthma or ACOS (asthma-COPD overlap syndrome)
• Respiratory infection or COPD exacerbation within 6 weeks (2 months if it resulted in hospitalization) prior to screening
• Clinically significant or relevant cardiovascular conditions, laboratory tests, electrocardiogram (ECG) parameters:
• Unstable angina/acute coronary syndrome, or Coronary Artery Bypass Grafting (CABG), Percutaneous Coronary Intervention (PCI) or myocardial infarction within the past 6 months.
• Congestive heart failure New York Heart Association (NYHA) class III/IV.
• Structural heart disease (hypertrophic cardiomyopathy, significant valvular disease).
• Paroxysmal (within the past 6 months) or symptomatic chronic cardiac tachyarrhythmia.
• Left bundle branch or high-degree AV block (second degree AV block type 2 and third degree AV block) unless the patient has a pacemaker.
• Sinus node dysfunction with pauses.
• Ventricular pre-excitation and/or Wolff-Parkinson-White syndrome.
• QTcF interval >470 msec (QT interval corrected using Fridericia's formula; QTcF=QT/[RR1/3]).
• Any other ECG abnormality deemed clinically significant by the Investigator.
• Bradycardia with ventricular rate < 45 bpm.
• Uncontrolled hypertension (> 165/95 mmHg).
• Clinically relevant respiratory conditions (other than COPD)
• Severe renal impairment eGFR < 30
• Hepatic impairment
• Narrow-angle glaucoma that, in the opinion of the Investigator, has not been adequately treated.
• Symptomatic prostatic hypertrophy or bladder neck obstruction/urinary retention that is clinically significant
• Patients not able to perform IOS, spirometry, plethysmography, or VT acquisition (10 min)
• Any contraindication to LABA or LAMA drugs or to Inhaled corticosteroids
• Pregnancy or breastfeeding
• Woman of childbearing age without effective contraception
• Any type of cancer within 5 years
• Patients under guardianship

Where it is running

• CHU de Lille — Lille, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.